Medicare Spending, Uptake Remain Low For New Alzheimer's Drugs

Medicare Spending, Uptake Remain Low For New Alzheimer's Drugs STAT reports how Leqembi and Kisunla, the recently approved Alzheimer's drugs, have had low uptake from those in need due to how hard they are to administer and their potential for severe side effects like brain bleeding. Also in the news: a pacemaker recall; a new cancer treatment; miniature therapy horses; and more. https://kffhealthnews.org/morning-breakout/not-ready-pharma-health-industry/